Oncology

The study, presented at the Society of Surgical Oncology Cancer Symposium, found that palliative surgery in patients with advanced cancers can relieve pain with minimal morbidity.

The study authors say their findings indicate that the cost of breast cancer overtreatment appears to be much higher than previously estimated. Their $4 billion figure is the midpoint of a range that depends upon assumptions about the rates of false-positive mammograms and breast cancer overdiagnosis.

In a large study conducted at the University of Pennsylvania in more than 31,000 women, scientists identified regions of both BRCA1 and BRCA2 that, when mutated, confer higher risks of ovarian cancer, and other regions that confer higher risk of breast cancer.

The retrospective study evaluated data collected between 1975 and 2011 from 2 large cancer studies that included 26 cancer centers in North America.

A test that uses gold nanoparticles to detect early-stage prostate cancer costs less than $1, returns results in minutes and is more accurate than standard PSA screening, pilot studies show.

By combining, in a liposome, magnetic nanoparticles and photosensitizers that are simultaneously and remotely activated by a magnetic field and light, scientists obtained total tumor regression in mice.

The trial, whose results were published in the Journal of Clinical Oncology, found that circulating tumor cells and lactose dehydrogenase are ideal surrogates to predict overall survival in patients with advanced prostate cancer.

One day, cancer treatment regimens might include vaccines specially tailored to each patient. In a small preliminary study published in Science, researchers report successful use of these vaccines in 3 patients.

Researchers at Dartmouth's Norris Cotton Cancer Center designed rehabilitation intervention to help women with breast cancer find ways to accelerate recovery and engage in health-promoting activities.

With a focus on improving quality while maintaining the cost of care, providers and payers are evaluating various payment models that could improve patient outcomes using evidence-based treatment at lower costs to the healthcare system.

While supporting the FDA's standards-based regulatory efforts to explore next generation sequencing tests as diagnostic tools, the American Society of Clinical Oncology warned against misinterpretation or over-interpretation of test results.

Research published by a team of Italian scientists in the Journal of the National Institute of Cancer shows that a 13-gene panel blood test for microRNAs could be a cost-effective screening tool for lung cancer, compared with low-dose CT, which is expensive.

With an aim to grab band-width in the shared PD-1 space, Merck has partnered with Syntax to conduct combination studies of Keytruda with Entinostat in melanoma and lung cancer patients.

The annual report was published in the March 30 issue of the Journal of the National Cancer Institute. The report was co-authored by experts from the North American Association of Central Cancer Registries, the American Cancer Society, CDC, and the National Cancer Institute.

Knowledge is power, as was the case with a doctoral student at MIT whose keen interest in his own medical data resulted in the diagnosis and excision of a brain tumor. But are all health systems ready to share patients' data with them?

The battle is being closely watched for signs that brand-name drug makers may be able to delay the introduction of biosimilars, which are cheaper versions of brand-name biologics.

The cost of care for patients receiving chemotherapy in community oncology clinics is lower than for comparable patients receiving chemotherapy in the hospital outpatient setting.

Hospitals like Boston Children's and Penn Medicine think they are better off building in-house apps that are custom-made for their workflow, rather than risk buying those available in the market, which may not necessarily be a perfect fit.

An excisional biopsy, which is common in case a breast lump is detected, involves an incision along the contour of the breast and removeing the lump. However, this procedure can result in pain, scarring and breast deformity.

Low pre-surgery uptake of a labeled glucose analogue, a marker of metabolic activity, in the primary tumor of patients with stage I non-small cell lung cancer is associated with increased overall survival and a longer time before tumor recurrence, a study shows. Patients with high labeled glucose uptake may benefit from additional therapy following surgery.

Studies presented at the annual meting of the Society of Gynecologic Oncology, in Chicago, evaluated the efficacy of an experimental vaccine and an angiogenesis inhibitor in preventing the recurrence of ovarian cancer.

A new study published by the IMS Institute for Healthcare Informatics finds that reimbursement approaches based on cost-per-quality-adjusted-life-year measures rather than drug effectiveness may limit access to innovative cancer treatments.

Two studies, published last week in Journal of Clinical Oncology, report improved survival as well as reduced caregiver burden following early initiation of palliative care in advanced cancer patients.

The Global Cancer Project Map is an interactive online database that allows users to search for cancer experts and research projects by country and by cancer type, and then to initiate contact with project principal investigators and program directors.

The study, published in The Journal of Community and Supportive Oncology, discovered cancer survivors perceive gaps in their care with respect to reviewing information, asking questions, obtaining answers, and making decisions.

The authors however cautioned that we still lack an understanding of biomarker-driven patient selection for PD-1 and PD-L1 agent. Adequate knowledge of the mechanism of action of these immuno-oncology agents could help optimize therapy, they add.

The ENABLE trial, conducted in rural regions of Vermont and New Hampshire, reports a positive impact on the 1-year survival of advanced cancer patients. A parallel study, ENABLE III, reported benefits to caregivers following early introduction of palliative care in these advanced cancer patients.

Currently, Keytruda is approved for patients with advanced melanoma previously treated with Yervoy and, in some patients, another type of drug as well. That second- and third-line status limits the number of patients eligible for the drug.

The NCI wants to encourage clinical trial investigators to review data from their completed clinical trials and treating oncologists to look back in their patient records to identify potential cases of exceptional responses and submit them for consideration in the initiative.

Diabetes is associated with more advanced stage breast cancer, according to a new study that confirms a strong link between diabetes and later stage breast cancer at diagnosis.